Chris Martin, Co-Founder of ADC Therapeutics, Leaves CEO Seat for Industry Specialist Ameet Mallik MyPharma Editions

Posted on Tuesday, May 10, 2022 ADC Therapeutics, a biotechnology company developing next-generation targeted antibody-drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. dr. Martin will serve on the board of directors as a non-executive member and chair the Science and … Read more